Page last updated: 2024-12-06

1,2,3,4-tetrahydro-7,12-dimethylbenz(a)anthracene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

**1,2,3,4-Tetrahydro-7,12-dimethylbenz(a)anthracene (DMBA)** is a potent polycyclic aromatic hydrocarbon (PAH) that is known to be a powerful carcinogen.

**Structure and Properties:**

* **Structure:** DMBA is a planar molecule with four fused benzene rings and two methyl groups attached at positions 7 and 12.
* **Properties:** It is a white crystalline solid that is poorly soluble in water but soluble in organic solvents.

**Carcinogenic Activity:**

DMBA is a highly potent and potent carcinogen, primarily affecting the skin and mammary glands. Its carcinogenic activity stems from its ability to:

* **Bind to DNA:** DMBA can bind to DNA, forming adducts that disrupt DNA replication and gene expression.
* **Generate reactive oxygen species (ROS):** DMBA can induce the formation of ROS, which can damage cellular components and contribute to tumor development.

**Research Importance:**

DMBA plays a crucial role in research as a model compound for studying:

* **Carcinogenesis:** It serves as a standard model for investigating the mechanisms of cancer development, particularly skin and breast cancer.
* **DNA damage and repair:** DMBA-induced DNA damage provides a valuable tool for studying DNA repair pathways and the role of DNA repair in cancer prevention.
* **Cellular signaling pathways:** DMBA can activate various signaling pathways involved in cell proliferation, differentiation, and apoptosis, providing insights into cancer cell behavior.
* **Environmental toxicology:** DMBA is found in environmental pollutants, such as smoke and tar, and serves as a model for studying the carcinogenic effects of PAHs.

**Applications in Research:**

DMBA is used in a variety of research settings, including:

* **Animal models:** DMBA is frequently used to induce skin tumors in mice and rats.
* **Cell culture studies:** DMBA can be applied to cultured cells to investigate its effects on DNA damage, cell cycle regulation, and gene expression.
* **Drug development:** DMBA-induced tumors provide a platform for testing the efficacy of anticancer drugs and preventative agents.

**Conclusion:**

1,2,3,4-Tetrahydro-7,12-dimethylbenz(a)anthracene (DMBA) is a potent carcinogen that plays a significant role in research related to cancer development, DNA damage, and environmental toxicology. Its ability to induce tumors and alter cellular processes makes it a valuable tool for studying cancer mechanisms and developing new treatments.

Cross-References

ID SourceID
PubMed CID49724
CHEMBL ID319383
MeSH IDM0102909

Synonyms (12)

Synonym
CHEMBL319383
1,2,3,4-tetrahydro-7,12-dimethylbenz(a)anthracene
benz(a)anthracene, 1,2,3,4-tetrahydro-7,12-dimethyl-
brn 3317395
7,12-dimethyl-1,2,3,4-tetrahydrobenz(a)anthracene
1,2,3,4-tetrahydro-dmba
th-dmba
7,12-dimethyl-1,2,3,4-tetrahydrobenzo[a]anthracene
67242-54-0
4-05-00-02449 (beilstein handbook reference)
DTXSID20217577
1,2,3,4-tetrahydro-7,12-dimethylbenz[a]anthracene
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID200692Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 100 strain) in absence of S9 fraction1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
AID200698Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA1537 strain) in absence of S9 fraction1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
AID200700Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA1537 strain) in presence of S9 fraction1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
AID200694Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 100 strain) in presence of S9 fraction1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
AID200697Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 98 strain) in presence of S9 fraction1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
AID200695Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 98 strain) in absence of S9 fraction1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (57.14)18.7374
1990's3 (42.86)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]